CDEK by Data4ThePeople
Sign in Sign up
← All organizations

CV Therapeutics

For profitContributed to NME

Also known as: CV Technologies

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Nov 1, 2005

First marketed drug

Jan 27, 2006

First NDA

Jan 27, 2006

Last known activity

Jul 1, 2007

Acquired by Gilead Sciences on Jan 1, 2009

Timeline

1990s

  1. Jan 1, 1990

    CV Therapeutics— Founded

2000s

  1. Jan 27, 2006

    ranolazine— NDA Organization

  2. Jan 1, 2009

    Gilead Sciences— Acquired By

Drugs by trial phase (3 distinct, 5 trials)

Phase 3 (1 own, 0 via acquisition)

Phase 2 (2 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (2)

Recent trials (5)

Details

Founded
Palo Alto, CA, US Jan 1, 1990
First NDA
Jan 27, 2006
Last known activity
Jul 1, 2007

Notes

Acquired by Gilead